藥明生物迴應被納入美國商務部“未經覈實名單”:對業務沒有影響
格隆匯2月8日丨據科創板日報,藥明生物迴應被納入美國商務部“未經覈實名單”稱:“未覈實名單”並不是更爲人所熟知的美國“實體名單”或“黑名單”,藥明生物一直在進口生物反應器的某些硬件控制器和某些中空纖維過濾器,這些控制器受美國出口管制,但在過去10年中已獲得美國商務部的批準。我們遵守所有美國出口管制法規。我們不會將這些物品再出口或轉售給任何其他實體。美國商務部有一個例行程序來驗證這些在現場的正確使用(即自用,不得轉售)。由於COVID-19大流行,該過程在過去兩年中尚未完成。這對我們的業務或對全球合作夥伴的持續服務沒有影響。由於上海和無錫的設施建設後不需要此類設備,因此對我們的進口影響非常小。我們還正在採取臨時措施,在檢查前將這些子公司從名單中刪除。7日,美國商務部官網新增33家中國單位列入“未經覈實名單(UVL)”,其中包括藥明生物。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.